SCHEMBL7008067

SCHEMBL7008067

CCN(O)c1nc2c(NCc3ccccc3)ncnc2n1C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 12/20 0.57
CCNB1 P14635 6/20 0.57
CCNB2 O95067 4/20 0.57
CCNB3 Q8WWL7 4/20 0.57
CDK2 P24941 4/20 0.57
TMIGD3 P0DMS9 3/20 0.51
ADORA2A P29274 3/20 0.51
ADORA1 P30542 3/20 0.51
ADORA2B P29275 2/20 0.51
RAB9A P51151 2/20 0.51
KMT2A Q03164 1/20 0.51
NPC1 O15118 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CDK5 Q00535 1/20 0.45
CCNE1 P24864 3/20 0.44
CDK4 P11802 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3877499 0.86 CDK1 (0.53) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL6919436 0.86 CDK1 (0.58) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL7008061 0.80 CDK1 (0.59) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL7006036 0.80 ADORA2A (0.66) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL7008070 0.78 CDK1 (0.57) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL8677222 0.78 CDK1 (0.57) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL2098867 0.78 CDK1 (0.63) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL2310972 0.77 CDK1 (0.58) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL30539284 0.73 CDK1 (1.00) CDK1CCNB1CCNB2CCNB3CDK2
SCHEMBL754120 0.73 CDK1 (1.00) CDK1CCNB1CCNB2CCNB3CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof USTAV EXPERIMENTALNI BOTANIKY AV CR 2003-10-09 US disclosed
EP-1147108-B1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF USTAV EX BOTAN AKADEMIE VED CE (CZ) 2003-08-13 EP disclosed
US-6552192-B1 Inhibiting cyclin dependent kinase proteins, viruses, and immunostimulation; antimitotic, antiviral, anticancinogenic, antidegenerative, immunosuppressive USTAU EXPERIMENTALNI BOTANIKY AV-CR (CZ) 2003-04-22 US disclosed
EP-1147108-A1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF Ustav Experimentalni Botaniky Akademie ved Ceské Republiky (CZ) 2001-10-24 EP disclosed
WO-2000043394-A1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF ÚSTAV EXPERIMENTÁLNÍ BOTANIKY AV CR (CZ) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof CDK4, CDK5, CCNI CDK1 6/4885CCNB1 63/4885CCNB2 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.